- Home
- RLMD vs NXL Comparison
RLMD vs NXL Comparison
Compare RLMD & NXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RLMD
- NXL
- Stock Information
- Founded
- RLMD 2004
- NXL 2010
- Country
- RLMD United States
- NXL United States
- Employees
- RLMD N/A
- NXL N/A
- Industry
- RLMD Biotechnology: Pharmaceutical Preparations
- NXL Medical Specialities
- Sector
- RLMD Health Care
- NXL Health Care
- Exchange
- RLMD Nasdaq
- NXL Nasdaq
- Market Cap
- RLMD 11.5M
- NXL 36.1M
- IPO Year
- RLMD N/A
- NXL 2022
- Fundamental
- Price
- RLMD $0.27
- NXL $2.07
- Analyst Decision
- RLMD Hold
- NXL Hold
- Analyst Count
- RLMD 4
- NXL 1
- Target Price
- RLMD $4.25
- NXL N/A
- AVG Volume (30 Days)
- RLMD 517.6K
- NXL 216.7K
- Earning Date
- RLMD 05-07-2025
- NXL 05-09-2025
- Dividend Yield
- RLMD N/A
- NXL N/A
- EPS Growth
- RLMD N/A
- NXL N/A
- EPS
- RLMD N/A
- NXL N/A
- Revenue
- RLMD N/A
- NXL $162,078.00
- Revenue This Year
- RLMD N/A
- NXL $56.86
- Revenue Next Year
- RLMD N/A
- NXL $167.44
- P/E Ratio
- RLMD N/A
- NXL N/A
- Revenue Growth
- RLMD N/A
- NXL 26.00
- 52 Week Low
- RLMD $0.24
- NXL $0.35
- 52 Week High
- RLMD $5.84
- NXL $4.49
- Technical
- Relative Strength Index (RSI)
- RLMD 35.11
- NXL 36.78
- Support Level
- RLMD $0.25
- NXL $1.95
- Resistance Level
- RLMD $0.29
- NXL $2.28
- Average True Range (ATR)
- RLMD 0.02
- NXL 0.28
- MACD
- RLMD 0.01
- NXL -0.05
- Stochastic Oscillator
- RLMD 32.11
- NXL 23.84
About RLMD Relmada Therapeutics Inc.
Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its lead product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.
About NXL Nexalin Technology Inc.
Nexalin Technology Inc designs and develops innovative neurostimulation products to uniquely and effectively help combat the ongoing global mental health epidemic. The company has developed an easy-to-administer medical device referred to as Generation 1 or Gen-1 that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit waveform at 4 milliamps during treatment and are presently classified by the U.S. Food and Drug Administration (FDA) as a Class II device.